Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2008-09-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm800564yPMID 18817366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.

  2008cited by this paper
• First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.

  2007cited by this paper
• Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance.

  2007cited by this paper
• The Kinetics of Inhibition of Human Acetylcholinesterase and Butyrylcholinesterase by Two Series of Novel Carbamates

  2007cited by this paper
• Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.

  2007cited by this paper
• Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).

  2006cited by this paper
• Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.

  2006cited by this paper
• Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.

  2006cited by this paper
• Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

  2005cited by this paper
• Modeling effects of oxyanion hole on the ester hydrolysis catalyzed by human cholinesterases.

  2005cited by this paper
• Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.

  2005cited by this paper
• Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

  2005cited by this paper
• Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

  2005cited by this paper
• Very fast empirical prediction and rationalization of protein pKa values

  2005cited by this paper
• Novel isosorbide-based substrates for human butyrylcholinesterase.

  2005cited by this paper
• Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.

  2005cited by this paper
• PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations

  2004cited by this paper
• Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products*

  2003cited by this paper
• Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine.

  2002cited by this paper
• Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate.

  2002cited by this paper
• Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

  2002cited by this paper
• Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase.

  2001cited by this paper
• Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin.

  2001cited by this paper
• The cholinergic hypothesis of Alzheimer’s disease: a review of progress

  1999cited by this paper
• Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.

  1999cited by this paper
• Butyrylcholinesterase in the life cycle of amyloid plaques

  1997cited by this paper
• Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.

  1997cited by this paper
• Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target.

  1995cited by this paper
• Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.

  1994cited by this paper
• Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein

  1991cited by this paper
• The cholinergic hypothesis of geriatric memory dysfunction.

  1982cited by this paper
• CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE

  1978cited by this paper
• Human memory and the cholinergic system. A relationship to aging?

  1974cited by this paper
• A new and rapid colorimetric determination of acetylcholinesterase activity.

  1961cited by this paper

• Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale

  2025cites this paper
• Discovery of Novel NO-Donor Containing hCA II Inhibitors with Retinal Ganglion Cell-Protective Effects for the Efficient Treatment of Glaucoma.

  2025cites this paper
• Improvements in the Production of Isosorbide Monomethacrylate Using a Biobased Catalyst and Liquid–Liquid Extraction Isolation for Modifications of Oil-Based Resins

  2024cites this paper
• Pathogenesis of Alzheimer's Disease and Diversity of 1,2,3-Triazole Scaffold in Drug Development: Design Strategies, Structural Insights, and Therapeutic Potential.

  2023cites this paper
• Solvents and detergents compatible with enzyme kinetic studies of cholinesterases.

  2023cites this paper
• Incorporation of an Isohexide Subunit Improves the Drug-like Properties of Bioactive Compounds.

  2023cites this paper
• Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.

  2022cites this paper
• Butyrylcholinesterase - BuChE: A Potential Target for Development of Drugs for Alzheimer's Disease Treatment

  2020cites this paper
• Bicyclic 5-5 Systems: Two Heteroatoms 1:1

  2020cites this paper
• Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors.

  2019cites this paper
• Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation.

  2019cites this paper
• Progress in Target Drug Molecules for Alzheimer's Disease.

  2019cites this paper
• Synthesis and Biological Activity of (Z)-Dialkylaminoalkylamides of N-Benzoyl-α,β-Dehydroamino Acids and Their Iodomethylates

  2018cites this paper
• Synthesis and the activity assessment of adamantylcontaining thiazolium inhibitors of butyrylcholinesterase

  2017cites this paper
• Novel butyrylcholinesterase inhibitors through pharmacophore modeling, virtual screening and DFT-based approaches along-with design of bioisosterism-based analogues.

  2017cites this paper
• Synthesis and biological evaluation of 8-hydroxy-2,7-naphthyridin-2-ium salts as novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).

  2017cites this paper
• Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.

  2017cites this paper
• An Efficient Synthesis of bi‐Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease

  2017cites this paper
• Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease

  2016influential citation
• A Novel Way To Radiolabel Human Butyrylcholinesterase for Positron Emission Tomography through Irreversible Transfer of the Radiolabeled Moiety

  2016cites this paper
• Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer’s Disease

  2016cites this paper
• Synthesis, Anticholinesterase, and Antibacterial Activity of N-Aroyl-a-Aminoacrylic Acid Dialkylaminoalkylamides

  2015cites this paper
• Discovery of isoalloxazine derivatives as a new class of potential anti-Alzheimer agents and their synthesis.

  2015cites this paper
• Dual inhibition of the α-glucosidase and butyrylcholinesterase studied by molecular field topology analysis.

  2014cites this paper
• Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease

  2014cites this paper
• Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.

  2014cites this paper
• The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.

  2012cites this paper
• Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation.

  2012cites this paper
• Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability.

  2010cites this paper
• Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics.

  2010cites this paper
• Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor.

  2010cites this paper
• Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.

  2009cites this paper